Bharat Biotech International Limited is an Indian biotechnology company headquartered in Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.
|Type||Private Limited Company|
|Headquarters||Genome Valley, Turakapally, Hyderabad|
|Krishna M. Ella|
(Chairman & MD)
|Subsidiaries||Chiron Behring Vaccines |
The company has been responsible for developing an eco-friendly recombinant and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC. They were one of the first to develop vaccines for viral diseases like Chikungunya and Zika. The company also produces vaccines for Japanese Encephalitis.
COVID-19 vaccine developmentEdit
In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine. On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for a developmental COVID-19 vaccine named Covaxin, from the Drugs Controller General of India (DCGI), Government of India. The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis. A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.
In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose intranasal vaccine (codenamed BBV154) for COVID-19 being developed in collaboration with the Washington University School of Medicine in St Louis, Missouri. It is currently undergoing clinical trials.
Attempted data theftEdit
- "WHO prequalifies new rotavirus vaccine". WHO. Retrieved 2 July 2020.
- "WHO recommends use of first typhoid conjugate vaccine". WHO. Retrieved 2 July 2020.
- Bureau, Our. "Bharat Biotech buys Chiron Behring Vaccines from GSK". The Hindu BusinessLine. Retrieved 1 July 2020.
- "Bharat Biotech International Ltd". www.bloomberg.com. Retrieved 3 July 2020.
- "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". www.bharatbiotech.com. Retrieved 30 June 2020.
- "Process for the preparation and purification of recombinant proteins". patents.google.com. US patent No US8956812B2. 23 August 2004.
- Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand; Kang, Gagandeep; Rathore, Sudeep Singh; Juvekar, Sanjay; Muliyil, Jayaprakash; Arya, Alok; Shaikh, Hanif; Abraham, Vinod; Vrati, Sudhanshu; Proschan, Michael; Kohberger, Robert; Thiry, Georges; Glass, Roger; Greenberg, Harry B; Curlin, George; Mohan, Krishna; Harshavardhan, G V J A; Prasad, Sai; Rao, T S; Boslego, John; Bhan, Maharaj Kishan (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet. 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMC 4532697. PMID 24629994.
- Kang, G (October 2006). "Rotavirus vaccines". Indian Journal of Medical Microbiology. 24 (4): 252–7. doi:10.4103/0255-0857.29382. PMC 2481304. PMID 17185842.
- "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol.
- "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원". CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어 (in Korean). 3 June 2020.
- "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016.
- "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". www.ivi.int. International Vaccine Institute. Retrieved 30 June 2020.
- Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S.; Sudhakar, B.; Rao, N. Bhuvaneswara; Kaushik, Yashpal; Gopinathan, K.; Hegde, Nagendra R.; Gore, Milind M.; Krishna Mohan, V.; Ella, Krishna M. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases. 212 (5): 715–725. doi:10.1093/infdis/jiv023. PMID 25601942.
- "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". Global Health Institute. Retrieved 30 June 2020.
- "Bharat Biotech ties up with US varsity for Covid vaccine". Hindustan Times. 20 May 2020.
- "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint. 9 May 2020.
- Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
- "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
- "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020.
- "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials". The Indian Express. 30 June 2020.
- "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020.
- "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol.
- "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.
- "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express. 25 July 2020.
- "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020.
- "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com.
- Das, Krishna N. (1 March 2021). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm". Reuters. Retrieved 1 March 2021.